46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000022364 | 2016/05/10 | 20/05/2016 | Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis | Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis - Effectiveness of minodronate in osteoporotic patients with rheumatoid arthritis | Osteoprotic patients with rheumatoid arthritis | The selection criteria is based on which treatment each patient wants to take Minodronate group: oral intake 50mg per month Minodronate plus active vitamin D group: oral intake 50mg minodronate per month and eldecalcitol 0.75ug per day after breakfast | Department of Orthopaedic Surgery Shinshu University School of Medicine | NULL | Complete: follow-up complete | 50years-old | 100years-old | Male and Female | 140 | Not applicable | Japan |
| 2 | JPRN-UMIN000011087 | 2012/04/11 | 01/07/2013 | Efficacy of monthly minodronate for the treatment of osteoporosis associated with rheumatoid arthritis after previous treatment with bisphosphonates | Efficacy of monthly minodronate for the treatment of osteoporosis associated with rheumatoid arthritis after previous treatment with bisphosphonates - Efficacy of monthly minodronate for osteoporosis in RA | Osteoporosis | Minodronic acid (50mg/month or 1mg/day) | Osaka University Graduate School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 100 | Not applicable | Japan |